Actinium Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Si prevede che Actinium Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 4.4% e 61.3% all'anno, mentre si prevede che l'EPS crescerà del 18.3% all'anno.

Informazioni chiave

4.4%

Tasso di crescita degli utili

18.3%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.1%
Tasso di crescita dei ricavi	61.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	03 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Previsioni di crescita degli utili e dei ricavi

NYSEAM:ATNM - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	7	-50	-33	-51	5
12/31/2025	15	-35	-38	-54	5
12/31/2024	N/A	-42	-46	-41	5
6/30/2024	0	-43	-34	-34	N/A
3/31/2024	0	-46	-40	-40	N/A
12/31/2023	0	-49	-47	-47	N/A
9/30/2023	N/A	-50	-48	-48	N/A
6/30/2023	0	-46	-42	-42	N/A
3/31/2023	0	-39	-1	-1	N/A
12/31/2022	1	-33	8	9	N/A
9/30/2022	1	-30	11	11	N/A
6/30/2022	1	-27	11	11	N/A
3/31/2022	1	-25	-21	-21	N/A
12/31/2021	1	-25	-21	-21	N/A
9/30/2021	1	-23	-22	-22	N/A
6/30/2021	1	-22	-22	-21	N/A
3/31/2021	1	-22	-22	-21	N/A
12/31/2020	N/A	-22	-22	-22	N/A
9/30/2020	N/A	-20	-20	-20	N/A
6/30/2020	N/A	-21	-21	-21	N/A
3/31/2020	N/A	-22	-22	-22	N/A
12/31/2019	N/A	-22	-22	-21	N/A
9/30/2019	N/A	-24	-21	-21	N/A
6/30/2019	N/A	-23	-22	-22	N/A
3/31/2019	N/A	-23	-21	-21	N/A
12/31/2018	N/A	-24	-21	-21	N/A
9/30/2018	N/A	-22	-20	-19	N/A
6/30/2018	N/A	-23	-19	-19	N/A
3/31/2018	N/A	-25	N/A	-22	N/A
12/31/2017	N/A	-27	N/A	-22	N/A
9/30/2017	N/A	-28	N/A	-23	N/A
6/30/2017	N/A	-28	N/A	-22	N/A
3/31/2017	N/A	-28	N/A	-21	N/A
12/31/2016	N/A	-24	N/A	-21	N/A
9/30/2016	N/A	-24	N/A	-21	N/A
6/30/2016	N/A	-22	N/A	-18	N/A
3/31/2016	N/A	-22	N/A	-17	N/A
12/31/2015	N/A	-21	N/A	-19	N/A
9/30/2015	N/A	-20	N/A	-20	N/A
6/30/2015	N/A	-22	N/A	-20	N/A
3/31/2015	N/A	-11	N/A	-18	N/A
12/31/2014	N/A	-25	N/A	-14	N/A
9/30/2014	N/A	-25	N/A	-11	N/A
6/30/2014	N/A	-20	N/A	-8	N/A
3/31/2014	N/A	-27	N/A	-6	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ATNM rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ATNM rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ATNM rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ATNM ( 61.3% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ATNM ( 61.3% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ATNM è previsto essere elevato tra 3 anni

Actinium Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Forecast breakeven date pushed back to 2026

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Consensus revenue estimates fall by 85%

Recent updates

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Consensus forecasts updated

Price target decreased to US$35.00

Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

New 90-day low: US$7.75

Actinium Pharmaceuticals, Inc. Appoints Mark Kubik as Chief Business Officer

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA Trial

New 90-day low: US$8.08